Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Soon
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(182)
•••
Comment by Chritterson Feb 06, 2021 6:45pm
149 Views
Post# 32494307

RE:RE:RE:RE:RE:Soon

RE:RE:RE:RE:RE:SoonI didnt find the Links on Sedr.This was released in the US on friday most likely why the rise up on Kaly in the states. Lot of people on here are just here for a quick buck, Maybe read up wghat your investing so you know whats going on with the company

Captainblk wrote:
Captainblk wrote:
polygraph46 wrote: Captain............I think the reason Kaly put the releases and latest info on Sedar is because they really don't want many to read it as not everyone looks at Sedar.  Kaly has been feeding fluff for the past three/four years. If you go back and look at some of GVHD news......its all very fluffy and then, lo and behold, they pull the pin it.
Besides releasing on Sedar.......Kaly likes to put out press releases after market close on ........wait for it.......Friday's.  You rarely see that. 
Kaly is in a huge credibility hole...period.  pg46
 

100%, Fridays after the bell is when i am always sure to check when there is news from them. esp. since the last several when they were active were all lackluster. 



also i think its hilarious that they released this on a saturday, after we called it out on them releasing on Fridays.... they probably read it here and delayed it to subvert expecations


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities